FDA Calls Novartis' Melanoma Combo Drug a Breakthrough Post author:Sam Post published:October 22, 2017 Post category:BioPharma The FDA based its decision on data from the COMBI-AD Phase III trial. Source: BioSpace You Might Also Like Bay Area's Medeor Therapeutics Bags $57M November 26, 2017 Meet the 5 Bay Area Biotech Entrepreneurs Under 30 November 14, 2017 This is the Average Interview Process Time for a Biopharma Job November 8, 2017
